Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7591368 | 0.88 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL5785800 | 0.82 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5788345 | 0.81 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL24335036 | 0.81 | PTGS2 (0.83) | PTGS2PTGS1 | |
| SCHEMBL5787610 | 0.81 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5675569 | 0.80 | PTGS2 (0.94) | PTGS2PTGS1 | |
| SCHEMBL5790839 | 0.79 | PTGS2 (0.67) | PTGS2PTGS1 | |
| SCHEMBL5789241 | 0.79 | MAPT (0.83) | PTGS2PTGS1 | |
| SCHEMBL5787163 | 0.79 | PTGS2 (0.73) | PTGS2PTGS1 | |
| SCHEMBL5787875 | 0.78 | PTGS2 (0.78) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1235812-B1 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LTD (GB) | 2006-02-01 | — | — | EP | claimed |
| US-20040192694-A1 | Use of COX-2 inhibitors as gastroprokinetics | MANGEL ALLEN WAYNE (US) | 2004-09-30 | — | — | US | claimed |
| US-6780869-B1 | SELECTIVE INHIBITOR OF COX-2; ANTIINFLAMMATORY AGENT | SMITHKLINE BEECHAM CORPORATION | 2004-08-24 | — | — | US | claimed |
| JP-2003521516-A | — | — | 2003-07-15 | — | — | JP | claimed |
| CN-1399633-A | Pyrimidine derivatives | GLAXO GROUP LTD (GB) | 2003-02-26 | — | — | CN | claimed |
| US-20030022897-A1 | Use of cox-2 inhibitors as gastroprokinetics | SMITHKLINE BEECHAM CORPORATION | 2003-01-30 | — | — | US | claimed |
| US-20030013717-A1 | Use of cox-2 inhibitors for constipation | GLAXO GROUP LIMITED (GB) | 2003-01-16 | — | — | US | claimed |
| EP-1259239-A2 | USE OF COX-2 INHIBITORS AS GASTROPROKINETICS | GLAXO GROUP LIMITED (GB) | 2002-11-27 | — | — | EP | claimed |
| EP-1251839-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF CONSTIPATION | GLAXO GROUP LIMITED (GB) | 2002-10-30 | — | — | EP | claimed |
| EP-1235812-A2 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LIMITED (GB) | 2002-09-04 | — | — | EP | claimed |
| WO-2001056573-A1 | USE OF COX-2 INHIBITORS AS GASTROPROKINETICS | GLAXO GROUP LIMITED (GB) | 2001-08-09 | — | — | WO | claimed |
| WO-2001056555-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF CONSTIPATION | GLAXO GROUP LIMITED (GB) | 2001-08-09 | — | — | WO | claimed |
| WO-2001038311-A2 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LIMITED (GB) | 2001-05-31 | — | — | WO | claimed |
| US-20070166336-A1 | Stable and palatable oral liquid sumatriptan compositions | WOCKHARDT EU OPERATIONS (SWISS) AG (CH) | 2007-07-19 | — | — | US | disclosed |
| WO-2007070504-A2 | STABLE AND PALATABLE ORAL LIQUID SUMATRIPTAN COMPOSITIONS | MORTON GROVE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1235812-B1 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LTD (GB) | 2006-02-01 | — | — | EP | disclosed |
| EP-1235812-A2 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LIMITED (GB) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001056573-A1 | USE OF COX-2 INHIBITORS AS GASTROPROKINETICS | GLAXO GROUP LIMITED (GB) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001056555-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF CONSTIPATION | GLAXO GROUP LIMITED (GB) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001038311-A2 | PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 | GLAXO GROUP LIMITED (GB) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192694-A1 | Use of COX-2 inhibitors as gastroprokinetics | PTGS2, PTGES2, PTGER2 | PTGS2 1/4885PTGS1 5/4885 |
| US-20030022897-A1 | Use of cox-2 inhibitors as gastroprokinetics | PTGS2, PTGES2, PTGER2 | PTGS2 1/4885PTGS1 5/4885 |
| US-20030013717-A1 | Use of cox-2 inhibitors for constipation | PTGS2, PTGES2, PTGER2 | PTGS2 1/4885PTGS1 5/4885 |
| US-20070166336-A1 | Stable and palatable oral liquid sumatriptan compositions | TAS2R39, TAS2R9, TAS2R8 | PTGS2 722/4885PTGS1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.